Prescription of obesity treatment, ‘Contrave’ started, competing against ‘Belviq’
Since the prescription of ‘Contrave(naltrexone+bupropion),’ an obesity therapy whose domestic exclusive sales agreement was established by Kwang Dong Pharmaceutical, started this month, interests have been focused on the obesity treatment market.
As Contrave emerged as a rival of Ildong Pharmac...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
